Table 2.
Multivariate Cox regression analyses of relapse rate in AML patients.
| B | SE | Wald | df | Sig. | Exp(B) | 95.0% CI for Exp(B) |
||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| KIR2DL2_or_2DS2 | −2.038 | 0.838 | 5.917 | 1 | 0.015 | 0.130 | 0.025 | 0.673 |
| aGvHD | 0.141 | 0.859 | 0.027 | 1 | 0.870 | 1.151 | 0.214 | 6.196 |
| cGvHD | −0.005 | 0.117 | 0.002 | 1 | 0.968 | 0.995 | 0.791 | 1.253 |
| Graft_type | 1.718 | 0.878 | 3.831 | 1 | 0.050 | 5.575 | 0.998 | 31.150 |
| GvHD prevention | 1.214 | 1.152 | 1.110 | 1 | 0.292 | 3.366 | 0.352 | 32.210 |
| Disease status | 2.299 | 0.937 | 6.022 | 1 | 0.014 | 9.968 | 1.589 | 62.546 |
Presence of donor KIR2DL2 and KIR2DS2 as well as good prognosis and using bone marrow as stem cell source has a beneficial influence on patients’ relapse-free survival.